Original Article

Effect on Non-Small Cell Lung Cancer after Combination of Driver Gene Mutations and Anti-PD -1/PD-L1 Immunotherapy as Well as Chemotherapy

Abstract

Background: We aimed to reveal the correlation between pathological indicators and PD-L1, between gene mutation status in lung cancer through clinico-pathological data and lung cancer-related gene mutation and PD-L1 expression analysis.
Methods: The study was conducted in . PD-L1 testing and targeted gene mutations detection were evaluated. The clinical characteristics of these non-small cell lung cancer (NSCLC) samples have been obtained. The groups were grouped according to clinico-pathological features and PD-L1 expression (Yes/No or High/Low), and the clinico-pathological and genetic and molecular features and correlation with PD-L1 expression were compared across the above groups. Comparisons and analyses were made between different treatment schemes.
Results: Lung adenocarcinoma (LUAD, n=142) and lung squamous carcinoma (LUSC, n=143) samples were enrolled (median age: 64 years old). Pleural invasion and M staging were significantly different from PD-L1 alterations (P<0.05). The percentage of patients with PD-L1 tumor proportion score (TPS)≥50% was 36.24% and the percentage of patients with PD-L1 TPS<50% was 29.53%. The percentage of patients with PD-L1 high-expressed and treated by immunotherapy was 75.93% and 63.41% experienced Partial Response/Complete Response. The mutations ratio of EGFR, ALK, KRAS, MET, RET and TP53 were 28.86%, 1.34%, 6.04%, 0.67%, 1.34% and 0.67%, respectively. KRAS mutation was significantly different from PD-L1 alterations (P<0.01).
Conclusion: There are individual differences in PD-L1 expression, which can also vary depending on the different clinical features. Specific molecular features correlate with differential PD-L1 expression and may influence the response to therapy.

1. Davidson MR, Gazdar AF, Clarke BE (2013). The pivotal role of pathology in the management of lung cancer. J Thorac Dis, 5 Suppl 5(Suppl 5):S463-78.
2. Reck M, Rodríguez-Abreu D, Robinson AG, et al (2016). Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med, 375(19):1823-1833.
3. Mok TSK, Wu YL, Kudaba I, et al (2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or meta-static non-small-cell lung cancer (KEY-NOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, 393(10183):1819-1830.
4. Kudura K, Ritz N, Kutzker T, et al (2022). Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphologi-cal and Metabolic Features of Primary Tumors. Cancers (Basel), 14(24):6095.
5. Seto K, Kuroda H, Yoshida T, et al (2018). Higher frequency of occult lymph node metastasis in clinical N0 pulmonary ad-enocarcinoma with ALK rearrangement. Cancer Manag Res, 10:2117-2124.
6. Herzberg B, Campo MJ, Gainor JF (2017). Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Oncologist, 22(1):81-88.
7. Han X, Fan J, Gu J, et al. (2020) CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas. Cancer Imaging, 20(1):51.
8. Bylicki O, Paleiron N, Margery J, et al (2017). Targeting the PD-1/PD-L1 Im-mune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. Target Oncol, 12(5):563-569.
9. Lindeman NI, Cagle PT, Aisner DL, et al (2018). Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of Ameri-can Pathologists, the International Asso-ciation for the Study of Lung Cancer, and the Association for Molecular Pa-thology. Arch Pathol Lab Med, 142(3):321-346.
10. Hsu PC, Jablons DM, Yang CT, You L (2019). Epidermal Growth Factor Recep-tor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). Int J Mol Sci, 20(15):3821.
11. Paver EC, Cooper WA, Colebatch AJ, et al (2021). Programmed death ligand-1 (PD-L1) as a predictive marker for immuno-therapy in solid tumours: a guide to im-munohistochemistry implementation and interpretation. Pathology, 53(2):141-156.
12. Wang Y, Wu J, Deng J, She Y, Chen C (2021). The detection value of PD-L1 expression in biopsy specimens and surgical resection specimens in non-small cell lung cancer: a meta-analysis. J Thorac Dis, 13(7):4301-4310.
13. Boothman AM, Scott M, Ratcliffe M, et al (2019). Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the AT-LANTIC Study. J Thorac Oncol, 14(8):1390-1399.
14. Kim S, Koh J, Kwon D, et al (2017). Com-parative analysis of PD-L1 expression between primary and metastatic pulmo-nary adenocarcinomas. Eur J Cancer, 75:141-149.
15. Garon EB, Rizvi NA, Hui R, et al (2015). Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med, 372(21):2018-28.
16. Borghaei H, Langer CJ, Paz-Ares L, et al (2020). Pembrolizumab plus chemother-apy versus chemotherapy alone in pa-tients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized con-trolled trials. Cancer, 126(22):4867-4877.
17. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al (2019). Nivolumab plus Ipili-mumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med, 381(21):2020-2031.
18. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al (2018). Pembrolizumab plus Chem-otherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med, 378(22):2078-2092.
19. Jiang L, Lin Z, Li N, et al (2021). [Correla-tion Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations]. Zhongguo Fei Ai Za Zhi, 24(9):623-631.
20. Bahnassy AA, Ismail H, Mohanad M, et al (2022). The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma pa-tients from Egypt. J Egypt Natl Canc Inst, 34(1):23.
21. Rangachari D, VanderLaan PA, Shea M, et al (2017). Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma. J Thorac Oncol, 12(5):878-883.
22. D'Incecco A, Andreozzi M, Ludovini V, et al (2015). PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer, 112(1):95-102.
Files
IssueVol 53 No 8 (2024) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v53i8.16280
Keywords
Non-small cell lung cancer (NSCLC) Gene mutations Prognostic analysis Immunotherapy
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Huang Z, Yu L, Chen W, Zhu D, Chen H. Effect on Non-Small Cell Lung Cancer after Combination of Driver Gene Mutations and Anti-PD -1/PD-L1 Immunotherapy as Well as Chemotherapy. Iran J Public Health. 2024;53(8):1754-1768.